Cerebrolysin 60mg/vial
Cerebrolysin 60mg/vial is presented as a neurotrophic peptide preparation intended for controlled clinical or research handling, depending on the source and jurisdiction. Cerebrolysin is used in some countries for cerebrovascular and neurocognitive disorders, including stroke, traumatic brain injury, vascular dementia and Alzheimer-type dementia.
Key Features
• Research-grade peptide (99+% purity, third-party tested)
• Neurotrophic peptide preparation associated with cerebrovascular and cognitive-support applications
• Publicly referenced for use in stroke, traumatic brain injury, vascular dementia and Alzheimer-type dementia
• Supplied here as a 60mg vial format
• Intended for controlled handling with strict attention to sterility, compatibility and product verification
• Country-specific prescribing and regulatory status may differ significantly
Product Specifications
Product Name: Cerebrolysin
Supplied As: 60mg lyophilized powder/vial (price is per vial)
Dosage Form: Vendor-specific vial presentation
Routes: Intramuscular or intravenous administration depending on volume
Regulatory status: Prescription status and approval vary by jurisdiction
Therapeutic Indications
Cerebrolysin is used in the treatment of cerebrovascular disorders, especially:
1. Senile dementia of Alzheimer's type
2. Vascular dementia
3. Stroke
4. Craniocerebral trauma including commotio and contusio
Handling and Preparation Notes
• Verify the exact formulation, concentration, sterility standard and excipients from the supplier before use.
• Maintain sterile technique throughout preparation and administration handling.
• Label prepared material clearly and store only under the conditions specified by the manufacturer or supplier.
Dosing and Reconstitution Guide:
Compatible Dilutants: Bacteriostatic Water, 0.9% NACl and Dextrose
Final concentration: 10mg/ml. At 10mg/ml: 60mg = 6ml - use a 10ml syringe for IV dilution.
Label with Date; Refrigerate at 2–8 °C. Use within 28 days.
Reconstitution
For Subcutaneous (IM) Administration: Reconstitute Cerebrolysin 60mg with 6ml bacteriostatic water for subcutaneous use (10mg/ml).Use at 60mg weekly (6ml); divide across multiple injection sites.
For IV infusion: dilute in 100ml 0.9% NaCl saline; infuse over 60 minutes x 10 days under medical supervision only.
CASTA trial: 30 ml daily IV for 10 days significantly improved NIHSS in acute ischemic stroke.
Ruether et al. 2001: 30 ml daily x 4 weeks improved MMSE by 3.2 points in Alzheimer's patients.
Safety Information
• Do not mix with other drugs in the same solution.
• Reported adverse reactions in public branded-product materials are generally described as transient and mild.
• Special care should be taken with sterile handling and administration.
• Contraindications listed in public branded materials include hypersensitivity to components, epilepsy and severe renal impairment.
• Country-specific prescribing information should be consulted for full warnings, precautions, interactions, pregnancy/lactation guidance and storage requirements.
Q & A
1. What is Cerebrolysin?
Cerebrolysin is a neuropeptide preparation publicly described by its manufacturer as a product used in some countries for stroke, traumatic brain injury, vascular dementia and Alzheimer's-type dementia.
2. Is Cerebrolysin officially sold as a 60mg lyophilized vial?
The branded public materials I found describe Cerebrolysin as a solution for injection, not as a standard lyophilized 60mg vial. A 60mg/vial format should therefore be treated as vendor-specific unless official labeling shows otherwise.
3. Can this 60mg/vial format be assumed to match the branded injectable product?
No. The presentation, concentration, excipients, sterility and preparation method may differ. Those details should be verified directly from the supplier's documentation.
4. What conditions is Cerebrolysin associated with in public prescribing information?
Public branded materials list Alzheimer's-type senile dementia, vascular dementia, stroke and craniocerebral trauma among the main indications.
5. Can Cerebrolysin be mixed with other drugs in the same solution?
It should not be mixed with other drugs in the same solution.
6. Are adverse effects common?
Adverse reactions are generally transient and mild, but full risk information depends on the jurisdiction-specific prescribing information and the exact product being used.
7. Is Cerebrolysin approved in the United States?
Cerebrolysin is not registered with the FDA and is not approved for sale or distribution in the United States.
Legal and Regulatory Note
Cerebrolysin is a prescription medication and prescribing information varies by country. It is not FDA-approved in the United States. By purchasing this product, you confirm that you are acquiring it for lawful research purposes. It is the purchaser’s responsibility to ensure compliance with local laws, institutional policies, ethical standards and customs requirements. Liability for misuse is disclaimed.
